A pharmaceutical company director is now banned from holding a director role at any UK company for the next five years after making illegal arrangements.
List view / Grid view
The UK’s Competition and Markets Authority (CMA) has fined four companies in because of anti-competitive practices in the supply of nortriptyline.
King Pharmaceuticals Limited and Alissa Healthcare Research Limited have admitted to sharing information to keep drug prices up.
The CMA has revealed findings that provisionally show that four pharmaceutical companies have broken the law.